Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
002720.KS Stock Summary
Top 10 Correlated ETFs
002720.KS
In the News
002720.KS Financial details
Company Rating
Neutral
Market Cap
144.39B
Income
-8.42B
Revenue
135.37B
Book val./share
4194.43
Cash/share
525
Dividend
-
Dividend %
-
Employees
257
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
-11.11
Forward P/E
-
PEG
0.35
P/S
0.84
P/B
1.56
P/C
11.05
P/FCF
111.88
Quick Ratio
-
Current Ratio
0.93
Debt / Equity
0.36
LT Debt / Equity
0.01
-
-
EPS (TTM)
-413.67
EPS next Y
-
EPS next Q
-
EPS this Y
-314.76%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
12.07%
Revenue last 5Y
4.03%
Revenue Q/Q
9.88%
EPS Q/Q
-84.99%
-
-
-
-
SMA20
25.43%
SMA50
13.34%
SMA100
22.45%
Inst Own
-
Inst Trans
-
ROA
-7%
ROE
-13%
ROC
-0.01%
Gross Margin
50%
Oper. Margin
-1%
Profit Margin
-7%
Payout
-
Shs Outstand
20.25M
Shs Float
11.7M
-
-
-
-
Target Price
-
52W Range
3530.0-8120.0
52W High
-28.57%
52W Low
+64.31%
RSI
59
Rel Volume
3.53
Avg Volume
838.75K
Volume
2.96M
Perf Week
26.22%
Perf Month
19.83%
Perf Quarter
50.26%
Perf Half Y
52.23%
-
-
-
-
Beta
0.634
-
-
Volatility
475.36%, 763.62%
Prev Close
-1.36%
Price
5800
Change
-8.08%
002720.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 5.48K | 6.14K | 5.91K | 6.88K | 6.68K | |
Net income per share | -235.01 | 103.66 | -76.77 | 193.47 | -415.49 | |
Operating cash flow per share | 177.85 | 239.97 | 473.54 | 353.72 | 176.52 | |
Free cash flow per share | -112.67 | -305.83 | 376.8 | 284.28 | 124.88 | |
Cash per share | 497.08 | 201.08 | 389.95 | 302.34 | 524.95 | |
Book value per share | 3.01K | 3.32K | 3.38K | 4.03K | 4.19K | |
Tangible book value per share | 2.93K | 3.25K | 3.32K | 3.97K | 4.15K | |
Share holders equity per share | 3.01K | 3.32K | 3.38K | 4.03K | 4.19K | |
Interest debt per share | 1.8K | 1.83K | 1.81K | 1.61K | 1.59K | |
Market cap | 81.04B | 185.42B | 112.87B | 106.64B | 118.69B | |
Enterprise value | 109.19B | 219.54B | 140.99B | 129.7B | 138.76B | |
P/E ratio | -17.02 | 84.17 | -72.55 | 29.98 | -14.1 | |
Price to sales ratio | 0.73 | 1.42 | 0.94 | 0.84 | 0.88 | |
POCF ratio | 22.49 | 36.36 | 11.76 | 16.4 | 33.2 | |
PFCF ratio | -35.5 | -28.53 | 14.78 | 20.4 | 46.92 | |
P/B Ratio | 1.33 | 2.63 | 1.65 | 1.44 | 1.4 | |
PTB ratio | 1.33 | 2.63 | 1.65 | 1.44 | 1.4 | |
EV to sales | 0.98 | 1.68 | 1.18 | 1.02 | 1.03 | |
Enterprise value over EBITDA | 26.14 | 23.12 | 35.09 | 12.05 | 62.65 | |
EV to operating cash flow | 30.3 | 43.05 | 14.69 | 19.94 | 38.81 | |
EV to free cash flow | -47.83 | -33.78 | 18.46 | 24.81 | 54.86 | |
Earnings yield | -0.06 | 0.01 | -0.01 | 0.03 | -0.07 | |
Free cash flow yield | -0.03 | -0.04 | 0.07 | 0.05 | 0.02 | |
Debt to equity | 0.58 | 0.54 | 0.52 | 0.39 | 0.36 | |
Debt to assets | 0.26 | 0.26 | 0.26 | 0.21 | 0.18 | |
Net debt to EBITDA | 6.74 | 3.59 | 7 | 2.14 | 9.06 | |
Current ratio | 1.03 | 0.9 | 0.88 | 1.01 | 0.94 | |
Interest coverage | 1.07 | 9.29 | -0.58 | 5.27 | -1.38 | |
Income quality | -0.76 | 2.32 | -6.17 | 1.84 | -0.42 | |
Dividend Yield | 0.01 | 0 | 0 | 0 | 0 | |
Payout ratio | -0.11 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.05 | 0.03 | 0.04 | 0.04 | 0.05 | |
Research and developement to revenue | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | |
Intangibles to total assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Capex to operating cash flow | -1.63 | -2.27 | -0.2 | -0.2 | -0.29 | |
Capex to revenue | -0.05 | -0.09 | -0.02 | -0.01 | -0.01 | |
Capex to depreciation | -1.81 | -3.2 | -0.44 | -0.28 | -0.25 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 3.99K | 2.78K | 2.42K | 4.19K | 6.26K | |
ROIC | -0.37 | 0.02 | -0.01 | 0.04 | -0.02 | |
Return on tangible assets | -0.04 | 0.02 | -0.01 | 0.03 | -0.05 | |
Graham Net | -1.45K | -1.98K | -1.84K | -1.65K | -2.36K | |
Working capital | 1.88B | -5.42B | -6.32B | 680.31M | -3.35B | |
Tangible asset value | 59.28B | 69.01B | 67.25B | 72.95B | 84.03B | |
Net current asset value | -12.5B | -25.19B | -23B | -13.98B | -29.32B | |
Invested capital | 0.58 | 0.54 | 0.52 | 0.39 | 0.36 | |
Average receivables | 33.76B | 29.24B | 23.88B | 22.25B | 21.44B | |
Average payables | 8.37B | 7.93B | 7.25B | 7.16B | 7.82B | |
Average inventory | 15.39B | 19.12B | 19.1B | 19.39B | 21.74B | |
Days sales outstanding | 113.22 | 67.22 | 72.41 | 59.81 | 59.7 | |
Days payables outstanding | 54.04 | 40.33 | 40.53 | 40.74 | 45.36 | |
Days of inventory on hand | 104.19 | 120.49 | 92.49 | 128.15 | 112.52 | |
Receivables turnover | 3.22 | 5.43 | 5.04 | 6.1 | 6.11 | |
Payables turnover | 6.75 | 9.05 | 9 | 8.96 | 8.05 | |
Inventory turnover | 3.5 | 3.03 | 3.95 | 2.85 | 3.24 | |
ROE | -0.08 | 0.03 | -0.02 | 0.05 | -0.1 | |
Capex per share | -290.52 | -545.81 | -96.74 | -69.44 | -51.64 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.61K | 1.68K | 1.76K | 1.59K | 1.74K | |
Net income per share | -64.49 | 43.19 | -309.37 | -128.08 | -19.22 | |
Operating cash flow per share | -95.92 | 170.27 | 35.89 | -51.68 | 30.11 | |
Free cash flow per share | -108.1 | 153.54 | 20.69 | -62.97 | 20.89 | |
Cash per share | 290.03 | 438.45 | 605.37 | 502.59 | 525 | |
Book value per share | 3.86K | 3.88K | 3.39K | 3.26K | 4.19K | |
Tangible book value per share | 3.81K | 3.83K | 3.34K | 3.21K | 4.15K | |
Share holders equity per share | 3.86K | 3.88K | 3.39K | 3.26K | 4.19K | |
Interest debt per share | 1.51K | 1.51K | 1.58K | 1.55K | 1.53K | |
Market cap | 111.17B | 86.05B | 84.05B | 78.17B | 118.67B | |
Enterprise value | 134.23B | 106.33B | 103.45B | 99.06B | 138.75B | |
P/E ratio | -22.48 | 25.82 | -3.35 | -7.53 | -76.24 | |
Price to sales ratio | 3.59 | 2.66 | 2.36 | 2.43 | 3.36 | |
POCF ratio | -60.47 | 26.19 | 115.63 | -74.69 | 194.63 | |
PFCF ratio | -53.65 | 29.05 | 200.61 | -61.3 | 280.47 | |
P/B Ratio | 1.5 | 1.15 | 1.23 | 1.18 | 1.4 | |
PTB ratio | 1.5 | 1.15 | 1.23 | 1.18 | 1.4 | |
EV to sales | 4.34 | 3.28 | 2.91 | 3.08 | 3.93 | |
Enterprise value over EBITDA | 259.96 | 39.55 | 5.68 | 6.34 | -293.77 | |
EV to operating cash flow | -73.01 | 32.37 | 142.31 | -94.65 | 227.55 | |
EV to free cash flow | -64.78 | 35.89 | 246.91 | -77.68 | 327.91 | |
Earnings yield | -0.01 | 0.01 | -0.07 | -0.03 | 0 | |
Free cash flow yield | -0.02 | 0.03 | 0 | -0.02 | 0 | |
Debt to equity | 0.39 | 0.38 | 0.46 | 0.47 | 0.36 | |
Debt to assets | 0.21 | 0.21 | 0.22 | 0.22 | 0.18 | |
Net debt to EBITDA | 44.66 | 7.54 | 1.07 | 1.34 | -42.5 | |
Current ratio | 1.01 | 1.07 | 0.95 | 0.93 | 0.94 | |
Interest coverage | -2.1 | 3.65 | 3.95 | -9.01 | -3.85 | |
Income quality | 1.49 | 3.94 | -0.12 | 0.4 | -1.57 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.04 | 0.04 | 0.47 | 0.59 | 0.07 | |
Research and developement to revenue | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | |
Intangibles to total assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Capex to operating cash flow | 0.13 | -0.1 | -0.42 | 0.22 | -0.31 | |
Capex to revenue | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | |
Capex to depreciation | -0.21 | -0.29 | -0.28 | -0.21 | -0.2 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 2.37K | 1.94K | 4.86K | 3.06K | 1.35K | |
ROIC | -0.01 | 0.01 | 0.02 | -0.03 | 0 | |
Return on tangible assets | -0.01 | 0.01 | -0.04 | -0.02 | 0 | |
Graham Net | -1.58K | -1.5K | -1.69K | -1.74K | -2.36K | |
Working capital | 680.31M | 3.24B | -2.99B | -4.23B | -3.35B | |
Tangible asset value | 72.95B | 73.84B | 67.6B | 65.07B | 84.03B | |
Net current asset value | -13.98B | -12.45B | -17.94B | -18.87B | -29.32B | |
Invested capital | 0.39 | 0.38 | 0.46 | 0.47 | 0.36 | |
Average receivables | 20.64B | 21.08B | 21.83B | 22.04B | 21.99B | |
Average payables | 7.98B | 7.86B | 8.12B | 7.71B | 8.2B | |
Average inventory | 22.44B | 22.2B | 21.74B | 21.48B | 21.44B | |
Days sales outstanding | 60.35 | 59.46 | 56.36 | 61.16 | 56.46 | |
Days payables outstanding | 40.7 | 47.54 | 39.43 | 42.75 | 42.57 | |
Days of inventory on hand | 128.02 | 121.87 | 110.68 | 118.11 | 105.6 | |
Receivables turnover | 1.49 | 1.51 | 1.6 | 1.47 | 1.59 | |
Payables turnover | 2.21 | 1.89 | 2.28 | 2.11 | 2.11 | |
Inventory turnover | 0.7 | 0.74 | 0.81 | 0.76 | 0.85 | |
ROE | -0.02 | 0.01 | -0.09 | -0.04 | 0 | |
Capex per share | -12.19 | -16.73 | -15.2 | -11.28 | -9.22 |
002720.KS Frequently Asked Questions
What is Kukje Pharma Co., Ltd. stock symbol ?
Kukje Pharma Co., Ltd. is a KR stock and trading under the symbol 002720.KS
What is Kukje Pharma Co., Ltd. stock quote today ?
Kukje Pharma Co., Ltd. stock price is $5800 today.
Is Kukje Pharma Co., Ltd. stock public?
Yes, Kukje Pharma Co., Ltd. is a publicly traded company.